ZWZehua Wang

Zehua Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zehua Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CCNE1 overexpression drives a cGAS–STING-dependent interferon response and sensitizes HRD-positive ovarian cancer to immune checkpoint blockade

    by Xueling Wang, Tian Chen, Zehua Wang, Chenyang Wang, Xuyao Xu, Moran Yang, Guodong Zhang, Yan Huang, Haiou Liu

    Homologous recombination deficiency (HRD) in high-grade serous ovarian carcinoma (HGSOC) canonically dictates sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors. Although CCNE1 amplification is generally mutually exclusive with BRCA mutations, CCNE1 overexpression paradoxically co-occurs with HRD in approximately 4%–12% of cases. We investigated the clinical impact and immune landscape of this concurrent phenotype to uncover novel therapeutic vulnerabilities. We stratified HGSOC patients from independent cohorts based on CCNE1 expression and HRD status to evaluate survival and therapeutic response. The tumor immune microenvironment was characterized using single-cell RNA sequencing and multiplex immunofluorescence. Mechanistic investigations were conducted using Brca1-deficient ID8 murine models, and the efficacy of anti-PD-1 therapy was assessed in vivo and ex vivo using the patient-derived tumor fragments (PDTFs) platform. Clinically, CCNE1 overexpression abrogated the survival advantage typically conferred by HRD. Biologically, however, CCNE1high/HRD tumors exhibited a highly inflamed microenvironment characterized by robust infiltration of polyfunctional CD8+ T cells and CXCL9+ tumor-associated macrophages. Mechanistically, CCNE1 overexpression in an HRD background exacerbated replication stress and reactive oxygen species (ROS) accumulation, leading to cytosolic DNA leakage. This triggered a cGAS–STING-dependent type I interferon response, which was reversed by STING inhibition or ROS scavengers. Consequently, CCNE1high/HRD tumors demonstrated profound sensitivity to anti-PD-1 treatment in syngeneic mouse models and the HGSOC PDTFs platform. CCNE1 overexpression in HRD ovarian cancer drives cGAS–STING-dependent inflammation, transforming genotoxin-refractory tumors into highly vulnerable targets for anti-PD-1 therapy.

  • Open Access

    Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells

    by Zehua Wang, Tao Pu, Weiwei Miao, Yi Gao, Jianwen Gao, Xinyan Zhang

    Objective Ovarian cancer is associated with the highest mortality rate among all malignant gynecological tumors. PolyADP-ribose polymerase (PARP) inhibitor maintenance therapy is the standard treatment strategy for this type of cancer, and olaparib is a widely used oral PARP inhibitor for tumors with BRCA mutations. The present study aimed to investigate the effects of olaparib in non-BRCA-mutated ovarian cancer and the potential mechanisms involved. Methods The antitumor effect of cisplatin alone or in combination with olaparib was analyzed in an ovarian cancer subcutaneous transplantation tumor model in nude mice. Furthermore, the differences in microRNA (miRNA) expression levels were analyzed using miRNA arrays. In addition, the effects of miR-125a-3p on the proliferation of non-BRCA-mutated (A2780 and OVCAR-3) ovarian cancer cells were detected using A Cell Counting Kit-8 and changes in the cell cycle were detected using flow cytometry. Furthermore, SPiDER-βGal was used to detect expression changes in cellular senescence, and the expression of DNA damage repair proteins was detected using western blot analysis. Results The results revealed that cisplatin plus olaparib significantly reduced tumor volume in mice subjected to subcutaneous tumor transplantation, and the expression of miR-125a-3p significantly increased with this treatment combination. The overexpression of miR-125a-3p could inhibit cell migration, invasion and induces cell cycle arrest. Conclusion On the whole, the present study demonstrates that the increased expression of miR-125a-3p induces DNA damage and senescence in ovarian cancer cells, which enhances the therapeutic sensitivity.


  • Tackling cellular senescence by targeting miRNAs

    by Zehua Wang, Jianwen Gao, Congjian Xu

    Cellular senescence, which is characterized by permanent proliferation arrest, has become an important target for the amelioration of various human diseases. The activity of senescent cells is mainly related to the senescence-associated secretory phenotype (SASP). The SASP can cause chronic inflammation in local tissues and organs through autocrine and paracrine mechanisms, and a series of factors secreted by senescent cells can deteriorate the cellular microenvironment, promoting tumor formation and exacerbating aging-related diseases. Therefore, avoiding the promotion of cancer is an urgent problem. In recent years, increased attention has been given to the mechanistic study of microRNAs in senescence. As important posttranscriptional regulators, microRNAs possess unique tissue-specific expression in senescence. MicroRNAs can regulate the SASP by regulating proteins in the senescence signaling pathway, the reverse transcriptase activity of telomerase, the generation of reactive oxygen species and oxidative damage to mitochondria. Numerous studies have confirmed that removing senescent cells does not cause significant side effects, which also opens the door to the development of treatment modalities against senescent cells. Herein, this review discusses the double-edged sword of cellular senescence in tumors and aging-related diseases and emphasizes the roles of microRNAs in regulating the SASP, especially the potential of microRNAs to be used as therapeutic targets to inhibit senescence, giving rise to novel therapeutic approaches for the treatment of aging-associated diseases.


  • Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib

    by Zehua Wang, Jianwen Gao, Yuko Ohno, Haiou Liu, Congjian Xu

    Senescence mechanisms are vital to resistance to long-term olaparib maintenance treatment. Recently, peroxisome proliferator-activated receptor-γ agonists (e.g., rosiglitazone) have been reported to ameliorate the senescence-like phenotype by modulating inflammatory mediator production. This study examined synergistic effects on the anti-tumor activity of rosiglitazone combined with olaparib in ovarian cancer treatment.


  • Open Access

    Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer

    by Zehua Wang, Jianwen Gao, Jiabing Zhou, Haiou Liu, Congjian Xu

    Wang Z, et al. J Gynecol Oncol. 2018 Aug;30:e26. https://doi.org/10.3802/jgo.2019.30.e26